U.S. Heparin Market COVID-19 Impact 2021-2026

U.S. Heparin Market COVID-19 Impact 2021-2026

With burgeoning demand for anticoagulant drugs driven by the rising prevalence of coronary artery diseases and venous thromboembolism, U.S. heparin market is poised to gain major momentum over the ensuing years. According to the Society of Thoracic Surgeons database, approximately 200,000 cases of coronary artery bypass grafting (CABG) are reported annually in the U.S. Furthermore, the number of cardiac surgeries involving either CABG procedures or valve replacement and repair procedures rose by over 6.5% during the same time span. With the increasing number of such procedures, demand for heparin anticoagulant is likely to increase tremendously over the foreseeable future. According to the GMI report, U.S. heparin market size is projected to surpass USD 1.0 billion at a significant growth rate of 7.2% through 2026.

Request for a sample copy of this report @ https://www.decresearch.com/request-sample/detail/4868

Insights into major segments that are likely to transform U.S. heparin market outlook over the forecast period of 2020-2026:

In terms of product, the low molecular weight heparin segment accounted for a substantial valuation of USD 535.4 million in the past and is anticipated to dominate the market over the subsequent years. This can be attributed to the extensive use of low molecular weight heparin in coagulation disorders treatment as well as in surgical procedures. Besides, the increasing prevalence of deep vein thrombosis (DVT) will also impel the demand for low molecular weight heparin. In addition, elevating product demand across several healthcare settings on account of the increasing burden of chronic and cardiovascular diseases will complement the segment growth further.

Based on the application spectrum, the coronary artery disease segment had recorded an appreciable valuation of USD 148.5 million in 2019 and is expected to grow over time. The growth can be credited to increasing demand for heparin treatment due to the rising incidence of coronary artery disease in the country. Based on a report by the Center for Disease Control and Prevention, coronary heart disease (CAD) is the most common heart disease in U.S., resulting in around 365,914 deaths in 2017. Further, the report also mentions that over 18.2 million adults in the age group of 20 years and above are suffering from CAD.

U.S heparin market is highly characterized by the online pharmacy segment, which according to numerous reports is estimated to grow exponentially over the upcoming years owing to the numerous benefits associated with it such as availability of a wide range of products, discounts, easy mobilization and doorstep delivery. Such benefits are likely to attract a large consumer base. Moreover, the increasing adoption of online shopping among the young population will further support segment growth. For the records, the segment had registered a sizeable market share of over 13.4% in 2019.

Apart from the above-mentioned segments and the growth inducing factors associated with them, strategic initiatives undertaken by the business players are also significantly contributing to the industry growth. Prominent industry players operating in U.S. heparin industry such as Amphastar Pharmaceutical, Pfizer, Sanofi, Fresenius Kabi, Shenzhen Hepalink, etc. are focusing on strategic partnerships, acquisitions, geographical expansion and new product launches to strengthen their market position. For instance, in 2019, Fresenius Kabi announced its plans of distributing preservative-free Heparin Sodium Injection named Simplist® in the U.S. According to the company, the product will be available in 5,000 USP units per 0.5 mL in the form of ready-to-administer prefilled syringes. Apparently, this initiative helped the company in expanding its geographical footprint.

Request for Customization @ https://www.decresearch.com/roc/4868

Citing another instance regarding strategic partnership, in 2020, Premier Inc. announced its partnership with Fresenius Kabi through its ProvideGx® program aimed at providing the healthcare professionals with single-use, pre-filled IV bags of heparin sodium injection, to manage the long-term supply of medication that is required while performing various hospital inpatient procedures.